You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ)控股子公司科倫博泰擬折價配股 淨籌19.43億港元加速產品研發商業化

格隆匯6月5日丨科倫藥業(002422.SZ)公佈,公司近日獲悉公司控股子公司四川科倫博泰生物醫藥股份有限公司(以下簡稱"科倫博泰")根據其股東大會的發行股份的一般性授權,於2025年6月5日與2名配售代理訂立配售協議,根據協議約定,配售代理同意促使向不少於6名承配人配售5,918,000股科倫博泰H股股份,配售價格爲331.8港元/股。

此次配售所得款項淨額預計爲19.43億港元,將用於科倫博泰的(1)產品的研發、臨牀試驗、註冊備案、製造及商業化;(2)提升內部研發技術能力、加強外部合作及拓展產品管線組合;(3)補充營運資金及作一般企業用途。

此次配售如依據配售協議的約定順利完成,科倫博泰的股份總數將變更爲233,185,969股,其中公司及全資子公司科倫國際發展有限公司合計直接持有科倫博泰約53.41%股份,公司仍爲科倫博泰的控股股東。

此次配售係爲滿足科倫博泰持續發展與業務增長所需資金需求,進一步拓寬其融資渠道,有利於促進科倫博泰業務發展,對公司及科倫博泰的經營和長期發展有積極影響,不存在損害公司及全體股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account